首页> 美国卫生研究院文献>other >Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney skin and vascular disease in lupus-prone MRL/lpr mice
【2h】

Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney skin and vascular disease in lupus-prone MRL/lpr mice

机译:对易患狼疮的MRL / lpr小鼠的肽基精氨酸脱亚氨酶抑制作用会破坏NET的形成并防御肾脏皮肤和血管疾病

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

ObjectivesAn imbalance between neutrophil extracellular trap (NET) formation and degradation has been described in systemic lupus erythematosus (SLE), potentially contributing to autoantigen externalisation, type I interferon synthesis and endothelial damage. We have demonstrated that peptidylarginine deiminase (PAD) inhibition reduces NET formation and protects against lupus-related vascular damage in the New Zealand Mixed model of lupus. However, another strategy for inhibiting NETs—knockout of NOX2—accelerates lupus in a different murine model, MRL/lpr. Here, we test the effects of PAD inhibition on MRL/lpr mice in order to clarify whether some NET inhibitory pathways may be consistently therapeutic across models of SLE.
机译:目的系统性红斑狼疮(SLE)中嗜中性粒细胞胞外陷阱(NET)的形成与降解之间存在失衡,可能导致自身抗原外化,I型干扰素合成和内皮损伤。我们已经证明,在新西兰混合性狼疮模型中,肽酰精氨酸脱亚氨酶(PAD)抑制作用可减少NET的形成并防止狼疮相关的血管损伤。但是,另一种抑制NET的策略(NOX​​2的敲除)可在不同的鼠模型MRL / lpr中加速狼疮。在这里,我们测试了PAD抑制对MRL / lpr小鼠的作用,以阐明某些NET抑制途径是否可能在SLE模型中始终具有治疗作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号